CG ONCOLOGY INC. - COMMON STOCK

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

24 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates

31 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

28 Mar 2025 06:00:00 By Nasdaq GlobeNewswire

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

24 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates

12 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

26 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

16 Dec 2024 15:05:00 By Nasdaq GlobeNewswire

CG Oncology Announces Pricing of Public Offering

12 Dec 2024 19:19:18 By Nasdaq GlobeNewswire

CG Oncology Announces Proposed Public Offering

11 Dec 2024 05:17:23 By Nasdaq GlobeNewswire

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

06 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

05 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024

02 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting

20 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates

12 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer

11 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

30 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

08 Aug 2024 07:23:15 By Nasdaq GlobeNewswire

CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec

18 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

06 Jun 2024 11:14:19 By Nasdaq GlobeNewswire

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

24 May 2024 07:00:00 By Nasdaq GlobeNewswire